Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

CEO Albert Bourla is waiting for the US government to decide whether to place a 25% tariff on pharmaceutical imports.

Pfizer’s chief executive, Albert Bourla, told investors that the uncertainty surrounding President Donald Trump’s proposed tariffs on imported medicines is ...

Pfizer CEO says tariffs are discouraging the company from investing in the US. Pfizer's full-year guidance does not factor in ...

The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts ...

Viking Therapeutics (VKTX) stock rises as Pfizer (PFE) plans to bolster its pipeline with cardiometabolic and other obesity drugs, through acquisitions. Read more here.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is ...

Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.